Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research and Development | December 16, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 16, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,829 |
Reported balance
After 2024-12-16 transaction · row 1
1 source rowRow 1 · 2024-12-16 · Tax withholding · Disposed 304 · Balance 48,829 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,849 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,849 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 4,605 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,605 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,931 | $610.49 | $2,399,836.19 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,092 F5 · price: Represents volume-weighted average price of sales of 3,931 shares of Company stock on August 5, 2022 at prices ranging from $610.00 to $610.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,044 | $609.62 | $1,855,683.28 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,023 F4 · price: Represents volume-weighted average price of sales of 3,044 shares of Company stock on August 5, 2022 at prices ranging from $609.00 to $609.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 610 | $608.70 | $371,307.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,067 F3 · price: Represents volume-weighted average price of sales of 610 shares of Company stock on August 5, 2022 at prices ranging from $608.03 to $608.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 724 | $607.47 | $439,808.28 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,677 F2 · price: Represents volume-weighted average price of sales of 724 shares of Company stock on August 5, 2022 at prices ranging from $607.00 to $607.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 176 | $606.78 | $106,793.28 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,401 F1 · price: Represents volume-weighted average price of sales of 176 shares of Company stock on August 5, 2022 at prices ranging from $606.60 to $606.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · derivative · entry 22 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 71,218 | $613.00 | $43,656,634.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,577 Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 95,000 | $270.43 | $25,690,850.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 335 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,795 Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 753 | $664.34 | $500,248.02 |
DisclosureSEC source: 0001708138-21-000104 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,130 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,494 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001708138-21-000093 · edgardoc.xml · derivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,494 Underlying: Common Stock · 12,494 shares Expires 2031-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000093 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,883 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 72,500 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-21-000018 · edgardoc.xml · derivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,500 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 50,352 | $632.45 | $31,845,122.40 |
DisclosureSEC source: 0001883850-21-000018 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,957 Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 72,500 | $179.13 | $12,986,925.00 |
DisclosureSEC source: 0001883850-21-000018 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2021 Filed Dec 6, 2021 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 4,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-21-000018 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 4,605 Read SEC document |
| November 29, 2021 Filed Dec 6, 2021 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 4,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-21-000018 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,809 Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,806 | $520.17 | $1,979,767.02 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,280 F3 · price: Represents volume-weighted average price of sales of 3,806 shares of Company stock on May 17, 2021 at prices ranging from $520.02 to $520.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,336 | $519.47 | $5,369,241.92 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,086 F2 · price: Represents volume-weighted average price of sales of 10,336 shares of Company stock on May 17, 2021 at prices ranging from $519.00 to $519.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,379 | $518.63 | $1,752,450.77 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,422 F1 · price: Represents volume-weighted average price of sales of 3,379 shares of Company stock on May 17, 2021 at prices ranging from $518.02 to $518.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · derivative · entry 12 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 40,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · derivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable on December 31, 2014, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2014. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 7,204 | $516.69 | $3,722,234.76 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,801 Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 12,500 | $52.03 | $650,375.00 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 27,775 | $516.69 | $14,351,064.75 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,505 Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 40,000 | $179.13 | $7,165,200.00 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed May 18, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000020 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,280 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000052 · edgardoc.xml · derivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2030-12-09 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000052 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,715 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024. Read SEC document |
| May 11, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,026 | $570.28 | $1,155,387.28 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380 F4 · price: Represents volume-weighted average price of sales of 2,026 shares of Company stock on May 11, 2020 at prices ranging from $570.00 to $570.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 11, 2020 at each separate price. Read SEC document |
| May 11, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,175 | $569.39 | $1,238,423.25 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,406 F3 · price: Represents volume-weighted average price of sales of 2,175 shares of Company stock on May 11, 2020 at prices ranging from $569.00 to $569.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 11, 2020 at each separate price. Read SEC document |
| May 11, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 792 | $568.71 | $450,418.32 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,581 F2 · price: Represents volume-weighted average price of sales of 792 shares of Company stock on May 11, 2020 at prices ranging from $568.00 to $568.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 11, 2020 at each separate price. Read SEC document |
| May 11, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 312 | $567.50 | $177,060.00 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,373 F1 · price: Represents volume-weighted average price of sales of 312 shares of Company stock on May 11, 2020 at prices ranging from $567.11 to $567.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 11, 2020 at each separate price. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · derivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: With respect to 75,000 underlying shares (of which 12,500 remain outstanding) the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 7,195 | $560.67 | $4,034,020.65 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:39 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 12,500 | $52.03 | $650,375.00 |
DisclosureSEC source: 0001708138-20-000054 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 357 | $524.26 | $187,160.82 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 357 shares of Company stock on April 14, 2020 at prices ranging from $524.00 to $524.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 758 | $522.37 | $395,956.46 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,737 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 758 shares of Company stock on April 14, 2020 at prices ranging from $522.00 to $522.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,595 | $521.32 | $831,505.40 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,495 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,595 shares of Company stock on April 14, 2020 at prices ranging from $521.01 to $521.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,096 | $520.43 | $1,090,821.28 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,090 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 2,096 shares of Company stock on April 14, 2020 at prices ranging from $520.01 to $520.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 422 | $519.85 | $219,376.70 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,186 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 422 shares of Company stock on April 14, 2020 at prices ranging from $519.27 to $519.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 267 | $518.54 | $138,450.18 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,608 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 267 shares of Company stock on April 14, 2020 at prices ranging from $518.14 to $518.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $517.99 | $1,035.98 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,079 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · derivative · entry 13 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 13,079 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · derivative.exercise_date: With respect to 75,000 underlying shares (of which 25,000 remain outstanding) the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 7,582 | $511.56 | $3,878,647.92 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,877 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 13,079 | $52.03 | $680,500.37 |
DisclosureSEC source: 0001708138-20-000034 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 31 | $468.56 | $14,525.36 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 30 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F24 · balance_after: Form one of two Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 227 | $465.42 | $105,650.34 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 29 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,411 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F23 · price: Represents volume-weighted average price of sales of 227 shares of Company stock on February 27, 2020 at prices ranging from $465.04 to $465.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 126 | $464.14 | $58,481.64 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 28 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,638 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F22 · price: Represents volume-weighted average price of sales of 126 shares of Company stock on February 27, 2020 at prices ranging from $464.13 to $464.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 123 | $463.10 | $56,961.30 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 27 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,764 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.